1 report no significant differences in rates of detection of high-risk cervical neoplasia among women who underwent screening by cytologic testing, testing for human papillomavirus (HPV) with the Hybrid Capture II assay, or visual inspection of the cervix with acetic acid (VIA). Reductions in mortality from cervical cancer were observed only among women screened by HPV testing. The unexpected lack of a correlation between detection rates reported for the screening tests and subsequent mortality rates requires careful consideration. Sankaranarayanan et al. acknowledge that unidentified differences in followup care, rather than differences in the performance of screening tests, account for differences in mortality between women screened by VIA in their current study and women screened by VIA in an earlier study. 2 The same logic, applied to the current data, suggests that unidentified differences in follow-up care, rather than nonsignificant differences among screening-test detection rates, account for differences in mortality among the groups of women who underwent screening. Within the political structures of many developing countries, there is genuine lack of support for cervical-cancer prevention efforts, 3 which may be further eroded by the questionable conclusion that only an unaffordable screening option is better than none at all. To the Editor: The study by the Indian Council of Medical Research showed that a down-staging effect of VIA and a reduction in the case fatality rate still hold in the Indian subcontinent. 1 The discrepancy between the authors' earlier findings and the current findings with regard to the benefits of VIA calls for more explanation. 2
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To the Editor:
In a previous article, 1 Sankaranarayanan et al. reported a decrease in cervicalcancer mortality with the use of VIA and the "screen and treat" approach, whereas the current article calls for multiple visits and treatment only of women with grade 2 or 3 cervical intraepithelial neoplasia confirmed on biopsy. In the current report, there is no discussion of this difference between the two studies.
The current data cast doubt on VIA, which is an invaluable asset to cervical-cancer prevention in developing countries. The benefit of VIA in lowresource settings is that it can be used to detect cervical precancer inexpensively and that it enables the examiner to institute immediate and appropriate therapy. This strategy decreases the risk that a patient with a potentially precancerous lesion will be lost to follow-up.
We strongly believe that the lack of survival benefit reported in the current article should not preclude the lifesaving results of screen-and-treat programs that have been demonstrated previously. To the Editor: Interest in implementing cervical-cancer prevention services in developing nations will probably peak as a result of the powerful evidence reported by Sankaranarayanan et al. Unfortunately, expenditures on health care and health care-related development assistance may shrink because of the ongoing global financial downturn. 1 In this scenario, the integration of cervical-cancer prevention services with other population-based health care programs may provide valuable opportunities for cost-effective initiation, expansion, and sustainability of these services.
Programs for the prevention and treatment of human immunodeficiency virus (HIV) infection and the acquired immunodeficiency syndrome (AIDS) are being implemented in many developing nations, where cervical-cancer incidence and mortality rates are also high. HIV-AIDS programs are slowly but substantially contributing to improved health infrastructures and increasing access to health care. 2 Integration of cervicalcancer prevention services within HIV-AIDS programs is an excellent opportunity to target women at highest risk for cervical cancer, as we recently showed in Zambia. 3, 4 Such efforts hold the promise of both saving lives from an eminently preventable cancer and strengthening the broader primary care context that is so essential for the sustainability of vertical health programs. ther, increasing the number of early cancers detected by extending screening to more women. In 1943, Dorfman 1 proposed a clever pooling approach for screening military recruits for syphilis. His idea was that if the available assay performs well under a dilution of 1:k, then one can assay pools of specimens, each based on k persons, testing only individual specimens if their pool tested positive. To screen N persons in a population with a low prevalence, α, the number of assays one would need to conduct, on average, would be only .
In the study by Sankaranarayanan et al., α was approximately 0.10. Suppose an assay tolerates a dilution of 1:3 and the budget permits N assays. Pooling in groups of three would require (0.6)N assays, and the number of women who could be screened would be (1/0.6)N, or 1.67N. Further gains would accrue if women who presented for screening could be grouped according to risk, with individual-level assays reserved for highrisk women and pooling used for lower-risk women.
